Xvivo Perfusion AB (publ)

LSE:0RKL Stock Report

Market Cap: SEK 13.4b

Xvivo Perfusion Valuation

Is 0RKL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RKL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 543.62
Fair Value
22.2% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: 0RKL (SEK423) is trading below our estimate of fair value (SEK543.62)

Significantly Below Fair Value: 0RKL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RKL?

Key metric: As 0RKL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0RKL. This is calculated by dividing 0RKL's market cap by their current earnings.
What is 0RKL's PE Ratio?
PE Ratio65.5x
EarningsSEK 204.27m
Market CapSEK 13.37b

Price to Earnings Ratio vs Peers

How does 0RKL's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RKL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.9x
AMS Advanced Medical Solutions Group
41.5x20.8%UK£461.9m
TSTL Tristel
29x17.5%UK£188.4m
CTEC ConvaTec Group
39.9x20.4%UK£4.9b
SPI Spire Healthcare Group
33.2x26.9%UK£939.7m
0RKL Xvivo Perfusion
65.5x22.1%SEK 13.4b

Price-To-Earnings vs Peers: 0RKL is expensive based on its Price-To-Earnings Ratio (65.5x) compared to the peer average (35.9x).

Price to Earnings Ratio vs Industry

How does 0RKL's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0RKL 65.5xIndustry Avg. 31.9xNo. of Companies8PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0RKL is expensive based on its Price-To-Earnings Ratio (65.5x) compared to the European Medical Equipment industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is 0RKL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RKL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio65.5x
Fair PE Ratio35.7x

Price-To-Earnings vs Fair Ratio: 0RKL is expensive based on its Price-To-Earnings Ratio (65.5x) compared to the estimated Fair Price-To-Earnings Ratio (35.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RKL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 423.00
SEK 525.33
+24.2%
7.5%SEK 567.00SEK 480.00n/a6
Jan ’26SEK 489.00
SEK 538.17
+10.1%
7.8%SEK 584.00SEK 480.00n/a6
Dec ’25SEK 471.13
SEK 538.17
+14.2%
7.8%SEK 584.00SEK 480.00n/a6
Nov ’25SEK 450.35
SEK 545.67
+21.2%
6.3%SEK 584.00SEK 480.00n/a6
Oct ’25SEK 502.00
SEK 549.00
+9.4%
6.6%SEK 584.00SEK 480.00n/a6
Sep ’25SEK 530.65
SEK 549.00
+3.5%
6.6%SEK 584.00SEK 480.00n/a6
Aug ’25SEK 515.40
SEK 549.00
+6.5%
6.6%SEK 584.00SEK 480.00n/a6
Jul ’25SEK 418.50
SEK 440.00
+5.1%
13.9%SEK 520.00SEK 340.00n/a6
Jun ’25SEK 431.00
SEK 408.00
-5.3%
12.0%SEK 468.00SEK 340.00n/a6
May ’25SEK 381.50
SEK 408.00
+6.9%
12.0%SEK 468.00SEK 340.00n/a6
Apr ’25SEK 275.00
SEK 382.60
+39.1%
9.0%SEK 425.00SEK 340.00n/a5
Mar ’25SEK 276.31
SEK 382.60
+38.5%
9.0%SEK 425.00SEK 340.00n/a5
Feb ’25SEK 284.52
SEK 389.60
+36.9%
7.8%SEK 425.00SEK 340.00n/a5
Jan ’25SEK 329.52
SEK 377.00
+14.4%
16.3%SEK 450.00SEK 280.00SEK 489.005
Dec ’24SEK 272.76
SEK 363.75
+33.4%
17.1%SEK 450.00SEK 280.00SEK 471.134
Nov ’24SEK 230.73
SEK 371.67
+61.1%
18.8%SEK 450.00SEK 280.00SEK 450.353
Oct ’24SEK 276.44
SEK 391.67
+41.7%
11.5%SEK 450.00SEK 340.00SEK 502.003
Sep ’24SEK 289.50
SEK 391.67
+35.3%
11.5%SEK 450.00SEK 340.00SEK 530.653
Aug ’24SEK 323.00
SEK 376.67
+16.6%
7.2%SEK 405.00SEK 340.00SEK 515.403
Jul ’24SEK 303.55
SEK 376.67
+24.1%
7.2%SEK 405.00SEK 340.00SEK 418.503
Jun ’24SEK 286.57
SEK 376.67
+31.4%
7.2%SEK 405.00SEK 340.00SEK 431.003
May ’24SEK 305.48
SEK 370.00
+21.1%
7.2%SEK 405.00SEK 340.00SEK 381.503
Apr ’24SEK 244.00
SEK 354.00
+45.1%
8.7%SEK 385.00SEK 312.00SEK 275.003
Mar ’24SEK 235.00
SEK 365.50
+55.5%
9.1%SEK 400.00SEK 312.00SEK 276.314
Feb ’24SEK 220.97
SEK 365.50
+65.4%
9.1%SEK 400.00SEK 312.00SEK 284.524
Jan ’24SEK 185.66
SEK 357.50
+92.6%
11.3%SEK 400.00SEK 291.00SEK 329.524
Analyst Price Target
Consensus Narrative from 6 Analysts
SEK 523.48
Fair Value
19.2% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 09:10
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xvivo Perfusion AB (publ) is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dylan van HaaftenBryan Garnier & Co
Maria Vara FernándezBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB